Atika Capital Management’s Roivant Sciences ROIV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$8.23M Buy
225,000
+8,000
+4% +$290K 0.67% 42
2026
Q2
$7.68M Buy
+217,000
New +$6.41M 0.5% 50
2024
Q3
– Sell
-400,000
Closed -$4.23M – 112
2024
Q2
$4.23M Sell
400,000
-134,980
-25% -$1.48M 0.41% 68
2024
Q1
$5.64M Sell
534,980
-205,000
-28% -$2.21M 0.56% 61
2023
Q4
$8.31M Buy
739,980
+194,980
+36% +$1.9M 1.11% 34
2023
Q3
$6.37M Buy
545,000
+146,500
+37% +$1.66M 0.84% 47
2023
Q2
$4.02M Sell
398,500
-86,500
-18% -$774K 0.4% 69
2023
Q1
$3.58M Sell
485,000
-75,000
-13% -$618K 0.53% 56
2022
Q4
$4.47M Buy
+560,000
New +$3.12M 0.64% 49

Other funds holding ROIV

Atika Capital Management's ROIV Position: Q3 2026 in Review

Atika Capital Management increased its Roivant Sciences (ROIV) stake by 3.7% in Q3 2026, buying an estimated $290K and bringing the position to 225,000 shares worth $8.23M. The position accounts for 0.67% of the portfolio, ranked #42.

Atika Capital Management first reported a position in ROIV in Q4 2022 and has held it in 9 quarters since. The position peaked at $8.31M in Q4 2023. 522 funds tracked by Wall St. Rank hold ROIV as of Q3 2026.

  • Atika Capital Management held 225,000 shares of Roivant Sciences worth $8.23M as of Q3 2026.
  • Atika Capital Management bought 8,000 Roivant Sciences shares in Q3 2026, an estimated $290K.
  • Roivant Sciences made up 0.67% of Atika Capital Management's portfolio in Q3 2026, its #42 holding.
  • Atika Capital Management first reported a position in Roivant Sciences in Q4 2022 and has held it in 9 quarters since.
  • Atika Capital Management's Roivant Sciences position peaked at $8.31M in Q4 2023.
  • 522 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2026.

Based on Atika Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.